{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:07:46Z","timestamp":1793642866736,"version":"4.5.1"},"reference-count":67,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T00:00:00Z","timestamp":1710806400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"The European Alliance of Associations for Rheumatology","award":["QoC016"],"award-info":[{"award-number":["QoC016"]}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1136\/ard-2024-225534","type":"journal-article","created":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T13:20:47Z","timestamp":1710854447000},"page":"760-774","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":80,"title":["Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis"],"prefix":"10.1016","volume":"83","author":[{"given":"Andreas","family":"Kerschbaumer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef S","family":"Smolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo J O","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Bertheussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xenofon","family":"Baraliakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Aletaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis G","family":"McGonagle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain B","family":"McInnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bente Appel","family":"Esbensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin L","family":"Winthrop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolf-Henning","family":"Boehncke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan W","family":"Schoones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Gossec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2024-225534_bib1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0049-0172(73)90035-8","article-title":"Psoriatic arthritis","volume":"3","author":"Moll","year":"1973","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard-2024-225534_bib2","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41584-023-01038-9","article-title":"Predominant ligament-centric soft-tissue involvement differentiates axial psoriatic arthritis from ankylosing spondylitis","volume":"19","author":"McGonagle","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"10.1136\/ard-2024-225534_bib3","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/annrheumdis-2011-200350","article-title":"European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies","volume":"71","author":"Gossec","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225534_bib4","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","article-title":"European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update","volume":"75","author":"Gossec","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225534_bib5","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225534_bib6","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1136\/annrheumdis-2020-219014","article-title":"Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225534_bib7","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","article-title":"Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Mease","year":"2020","journal-title":"Lancet"},{"key":"10.1136\/ard-2024-225534_bib8","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1136\/annrheumdis-2021-221019","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 keepsake 1 trial","volume":"81","author":"Kristensen","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225534_bib9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0140-6736(22)02302-9","article-title":"Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled","volume":"401","author":"McInnes","year":"2023","journal-title":"The Lancet"},{"key":"10.1136\/ard-2024-225534_bib10","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/art.42519","article-title":"Efficacy and safety of the Tyk2\/Jak1 inhibitor brepocitinib for active psoriatic arthritis: a phase IIb randomized controlled trial","volume":"75","author":"Mease","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2024-225534_bib11","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2021-221664","article-title":"Efficacy and safety of selective Tyk2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis","volume":"81","author":"Mease","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225534_bib12","first-page":"312","article-title":"Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PSA 2","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225534_bib13","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1093\/rheumatology\/keab628","article-title":"Response to secukinumab on synovitis using power doppler ultrasound in psoriatic arthritis: 12-week results from a phase III study, ULTIMATE","volume":"61","author":"D\u2019Agostino","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2024-225534_bib14","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1136\/annrheumdis-2020-218808","article-title":"Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial","volume":"80","author":"Baraliakos","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225534_bib15","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1136\/annrheumdis-2019-216500","article-title":"GO-DACT: a phase 3B randomised, double-blind, placebo-controlled trial of golimumab plus methotrexate (MTX) versus placebo plus MTX in improving dactylitis in MTX-naive patients with psoriatic arthritis","volume":"79","author":"Vieira-Sousa","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225534_bib16","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","article-title":"Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3B trial","volume":"395","author":"McInnes","year":"2020","journal-title":"Lancet"},{"key":"10.1136\/ard-2024-225534_bib17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","article-title":"A head-to-head comparison of the efficacy and safety of Ixekizumab and adalimumab in biological-na\u00efve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial","volume":"79","author":"Mease","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225534_bib18","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","article-title":"Trial of upadacitinib and adalimumab for psoriatic arthritis","volume":"384","author":"McInnes","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2024-225534_bib19","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1016\/S2665-9913(22)00028-5","article-title":"Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis (COMPLETE-PSA): a double-blind, placebo-controlled, randomised, trial","volume":"4","author":"Mulder","year":"2022","journal-title":"The Lancet Rheumatology"},{"key":"10.1136\/ard-2024-225534_bib20","doi-asserted-by":"crossref","first-page":"e262","DOI":"10.1016\/S2665-9913(22)00008-X","article-title":"Comparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL): a randomised, open-label, two-part, phase 4 study","volume":"4","author":"Coates","year":"2022","journal-title":"The Lancet Rheumatology"},{"key":"10.1136\/ard-2024-225534_bib21","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1136\/annrheumdis-2022-222260","article-title":"Treat-to-target dose reduction and withdrawal strategy of TNF inhibitors in psoriatic arthritis and axial spondyloarthritis: a randomised controlled non-inferiority trial","volume":"81","author":"Michielsens","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225534_bib22","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2024-225534_bib23","article-title":"Comorbidities in early psoriatic arthritis: data from METAPSA cohort study","author":"Ishchenko","year":"2023","journal-title":"Arthritis care & research"},{"key":"10.1136\/ard-2024-225534_bib24","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1136\/annrheumdis-2020-217163","article-title":"Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis","volume":"79","author":"Kerschbaumer","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225534_bib25","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/ard-2024-225531","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update","volume":"83","author":"Gossec","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225534_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1136\/ard-2024-225534_bib28","author":"Wells"},{"key":"10.1136\/ard-2024-225534_bib29","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3899\/jrheum.210912","article-title":"Secukinumab in United States biologic-na\u00efve patients with psoriatic arthritis: results from the randomized, placebo-controlled CHOICE study","volume":"49","author":"Nguyen","year":"2022","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2024-225534_bib30","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40744-019-0163-5","article-title":"Efficacy and safety of subcutaneous secukinumab 150 mg with or without loading regimen in psoriatic arthritis: results from the FUTURE 4 study","volume":"6","author":"Kivitz","year":"2019","journal-title":"Rheumatol Ther"},{"key":"10.1136\/ard-2024-225534_bib31","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/S2665-9913(22)00329-0","article-title":"Methotrexate plus ustekinumab versus Ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3B, non-inferiority trial","volume":"5","author":"Koehm","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"10.1136\/ard-2024-225534_bib32","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1136\/annrheumdis-2020-217372","article-title":"Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of Ixekizumab versus adalimumab in patients with psoriatic arthritis na\u00efve to biological disease-modifying antirheumatic drug: final results by week 52","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"10.1136\/ard-2024-225534_bib33","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1136\/annrheumdis-2021-eular.1562","article-title":"Pos1044 effect of secukinumab versus adalimumab on ACR core components and health-related quality of life in patients with psoriatic arthritis: results from the exceed study","volume":"80","author":"Goupille","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225534_bib34","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1007\/s40744-021-00379-9","article-title":"Improvement in patient-reported outcomes in patients with Psoriatic arthritis treated with Upadacitinib versus placebo or Adalimumab: results from SELECT-PSA 1","volume":"8","author":"Strand","year":"2021","journal-title":"Rheumatol Ther"},{"key":"10.1136\/ard-2024-225534_bib35","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","article-title":"Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"key":"10.1136\/ard-2024-225534_bib36","doi-asserted-by":"crossref","first-page":"e715","DOI":"10.1016\/S2665-9913(21)00105-3","article-title":"Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies","volume":"3","author":"Mease","year":"2021","journal-title":"The Lancet Rheumatology"},{"key":"10.1136\/ard-2024-225534_bib37","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1136\/annrheumdis-2021-220991","article-title":"Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIB","volume":"81","author":"Coates","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225534_bib38","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/annrheumdis-2021-221048","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 keepsake 2 trial","volume":"81","author":"\u00d6st\u00f6r","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225534_bib39","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1093\/rheumatology\/keac342","article-title":"Risankizumab improved health-related quality of life, fatigue, pain and work productivity in psoriatic arthritis: results of keepsake 1","volume":"62","author":"Kristensen","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2024-225534_bib40","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002286","article-title":"Improved patient-reported outcomes in patients with psoriatic arthritis treated with risankizumab: analysis of the phase 3 trial keepsake 2","volume":"8","author":"Ostor","year":"2022","journal-title":"RMD Open"},{"key":"10.1136\/ard-2024-225534_bib41","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0140-6736(22)02303-0","article-title":"Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-A inhibitors: a randomised, double-blind","volume":"401","author":"Merola","year":"2023","journal-title":"The Lancet"},{"key":"10.1136\/ard-2024-225534_bib42","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1136\/annrheumdis-2019-216835","article-title":"Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"10.1136\/ard-2024-225534_bib43","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1136\/annrheumdis-2022-eular.536","article-title":"Op0258 Izokibep (Aby-035) in patients with active psoriatic arthritis \u2013 16-week results from a phase 2 study","volume":"81","author":"Behrens","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225534_bib46","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1136\/annrheumdis-2015-208466","article-title":"Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis","volume":"75","author":"Ramiro","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225534_bib47","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1136\/ard.2011.150995","article-title":"A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis","volume":"71","author":"Ash","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225534_bib48","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1001\/jama.2021.21316","article-title":"Effect of therapeutic drug monitoring vs standard therapy during maintenance Infliximab therapy on disease control in patients with immune-mediated inflammatory diseases: a randomized clinical trial","volume":"326","author":"Syversen","year":"2021","journal-title":"JAMA"},{"key":"10.1136\/ard-2024-225534_bib49","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1001\/jama.2021.4172","article-title":"Effect of therapeutic drug monitoring vs standard therapy during Infliximab induction on disease remission in patients with chronic immune-mediated inflammatory diseases: a randomized clinical trial","volume":"325","author":"Syversen","year":"2021","journal-title":"JAMA"},{"key":"10.1136\/ard-2024-225534_bib50","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/03009742.2022.2028364","article-title":"Interval prolongation of etanercept in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a randomized controlled trial","volume":"52","author":"Ruwaard","year":"2023","journal-title":"Scandinavian Journal of Rheumatology"},{"key":"10.1136\/ard-2024-225534_bib51","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1002\/art.41716","article-title":"Withdrawing Ixekizumab in patients with psoriatic arthritis who achieved minimal disease activity: results from a randomized, double-blind withdrawal study","volume":"73","author":"Coates","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2024-225534_bib52","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1016\/S2665-9913(20)30339-8","article-title":"Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL balance","volume":"3","author":"Nash","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1136\/ard-2024-225534_bib54","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002735","article-title":"Safety profile of Upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis","volume":"9","author":"Burmester","year":"2023","journal-title":"RMD Open"},{"key":"10.1136\/ard-2024-225534_bib55","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s40744-022-00507-z","article-title":"Influenza adverse events in patients with rheumatoid arthritis, ulcerative colitis, or psoriatic arthritis in the tofacitinib clinical development programs","volume":"10","author":"Winthrop","year":"2023","journal-title":"Rheumatol Ther"},{"key":"10.1136\/ard-2024-225534_bib56","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jamadermatol.2020.3257","article-title":"Association of secukinumab treatment with tuberculosis reactivation in patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis","volume":"157","author":"Elewski","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1136\/ard-2024-225534_bib57","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-034356","article-title":"Tuberculosis among patients treated with TNF inhibitors for rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis in Slovenia: a cohort study","volume":"10","author":"Rotar","year":"2020","journal-title":"BMJ Open"},{"key":"10.1136\/ard-2024-225534_bib58","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/rheumatology\/keac358","article-title":"Is the risk of infection higher during treatment with secukinumab than with TNF inhibitors? an observational study from the nordic countries","volume":"62","author":"Glintborg","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2024-225534_bib59","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1002\/acr.24630","article-title":"Risk of hospitalization for serious infection after initiation of ustekinumab or other biologics in patients with psoriasis or psoriatic arthritis","volume":"74","author":"Jin","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1136\/ard-2024-225534_bib60","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/annrheumdis-2019-216102","article-title":"Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis","volume":"79","author":"Li","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225534_bib61","first-page":"3834","article-title":"Risk of serious infections in arthritis patients treated with biological drugs: a matched cohort study and development of prediction model","volume":"60","author":"Krabbe","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2024-225534_bib62","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1136\/ard-2022-222879","article-title":"Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the Psabio real-world study","volume":"82","author":"Gossec","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225534_bib64","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1136\/annrheumdis-2019-216761","article-title":"Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data","volume":"79","author":"Mease","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225534_bib65","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/rheumatology\/keab522","article-title":"Risk of major adverse cardiovascular events in patients initiating biologics\/apremilast for psoriatic arthritis: a nationwide cohort study","volume":"61","author":"Pina Vegas","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2024-225534_bib68","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/bjd.20136","article-title":"The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up","volume":"185","author":"Lebwohl","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1136\/ard-2024-225534_bib69","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/rheumatology\/key241","article-title":"Malignancy and mortality rates in patients with severe psoriatic arthritis requiring tumour-necrosis factor alpha inhibition: results from the British Society for Rheumatology Biologics register","volume":"58","author":"Fagerli","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2024-225534_bib70","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1093\/rheumatology\/keaa828","article-title":"Risk of solid cancers overall and by subtypes in patients with psoriatic arthritis treated with TNF inhibitors - a nordic cohort study","volume":"60","author":"Hellgren","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2024-225534_bib71","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002776","article-title":"Haematological malignancies in patients with psoriatic arthritis overall and treated with TNF inhibitors: a nordic cohort study","volume":"8","author":"Cordtz","year":"2022","journal-title":"RMD Open"},{"key":"10.1136\/ard-2024-225534_bib73","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s40264-019-00797-3","article-title":"Ustekinumab safety in psoriasis, psoriatic arthritis, and Crohn\u2019s disease: an integrated analysis of phase II\/III clinical development programs","volume":"42","author":"Ghosh","year":"2019","journal-title":"Drug Saf"},{"key":"10.1136\/ard-2024-225534_bib74","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2019-000349","article-title":"Antitumour necrosis factor-A agents and development of new-onset cirrhosis or non-alcoholic fatty liver disease: a retrospective cohort","volume":"7","author":"Tang","year":"2020","journal-title":"BMJ Open Gastroenterol"},{"key":"10.1136\/ard-2024-225534_bib75","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1111\/jdv.16231","article-title":"The risk of treated anxiety and treated depression among patients with psoriasis and psoriatic arthritis treated with apremilast compared to biologics, dmards and corticosteroids: a cohort study in the United States Marketscan database","volume":"34","author":"Vasilakis-Scaramozza","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724001328?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724001328?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2024-225534","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T04:01:32Z","timestamp":1779249692000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724001328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":67,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S0003496724001328"],"URL":"https:\/\/doi.org\/10.1136\/ard-2024-225534","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2024-225534","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2024 \u00a9 European Alliance of Associations for Rheumatology, EULAR 2024. Re-use permitted under CC BY-NC-ND. No commercial re-use. No derivatives. See rights and permissions. Published by Elsevier Inc. on behalf of EULAR. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}